Close Menu

Grants

Additional funding opportunities

Research Funding Opportunities

Tools to Find Funding

Grants Awarded for Health Sciences Research

Title Typesort descending $ Amount Activity Investigator Unit Sponsor Date
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate The Efficacy and Safety of Anamorelin HCL for the Treatment OF Malignancy Associated Weight Loss and Anorexia... Contract $42,626.00 Clinical Trial Charles Hsu Cancer Center Division PSI Pharma Support America, Incorporated 01/2020
TruGraf Long-term Clinical Outcomes Study Contract Clinical Trial VENKATESH KUMAR ARIYAMUTHU Medicine Transplant Genomics, Inc. 03/2021
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with Either Durvalumab Monotherapy or Durvalumab Plus Bevacizumab Contract $208,612.70 Clinical Trial Gregory Woodhead Cancer Center Division Astrazeneca 06/2020
FEnofibRate as a Metabolic INtervention for Coronavirus Disease 2019 (COVID-19): A Randomized Controlled Trial (FERMIN trial) Contract $5,450.00 Clinical Trial Nancy Sweitzer Medicine University of Pennsylvania 01/2021
Rapid Immunoassay for Diagnosis of Coccidioidomycosis Contract $49,999.00 Research John Galgiani Valley Fever Ctr for Excellnc DxDiscovery 09/2020
iCLAS for Persistent Atrial Fibrillation Contract $193,319.94 Clinical Trial Wilber Su COM Phx Internal Medicine Adagio Medical, Inc 02/2021
A Phase III, Randomised, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with... Contract $1,278,228.50 Clinical Trial Charles Hsu Radiation Oncology Astrazeneca 08/2020
A Phase 2 Open-Label Study of Brentuximab Vedotin in Front-Line Therapy of Hodgkin Lymphoma (HL) and CD30-Expressing Peripheral T-cell Lymphoma (PTCL) in Adults Age 60 and Above Contract $147,691.00 Clinical Trial Daniel Persky Cancer Center Division Seattle Genetics, Incorporated 05/2020
Noninterventional Epigenomic Mapping of CD34+ Cells From Healthy Participants and Patients With Myelofibrosis (MF) and Polycythemia Vera (PV) Contract $74,529.50 Clinical Trial Krisstina Gowin Cancer Center Division Incyte Corporation 12/2020
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects with Heart Failure with Reduced Ejection Fraction... Contract $105,851.40 Clinical Trial Aaron Wolfson Sarver Heart Center Cytokinetics, Incorporated 09/2020
SAVAHCS: IPA for Josh Crossman Contract $41,154.48 Research Rick Schnellmann Pharmacy Administration United States Department of Veterans Affairs 02/2020
Invasive Cardiopulmonary Exercise Testing to Phenotype Post Pulmonary Embolism Dyspnea Contract $99,577.00 Clinical Trial Michael Insel Medicine Bayer Healthcare Pharmaceuticals Incorporated 11/2020
A Phase Ib/II Study of APG-115 in Combination with Pembrolizumab in Patients with Unresectable or Metastatic Melanomas or Advanced Solid Tumors Contract $513,891.00 Clinical Trial Montaser Shaheen Cancer Center Division Ascentage Pharma 01/2020
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Patients with COVID-19 Pneumonia Contract $3,236,387.50 Clinical Trial Sachin Chaudhary Medicine Syneos Health 06/2020
Nitric Oxide Treatment In COVID-19 Evaluation (NOTICE) Contract $18,455.00 Clinical Trial Thomas Ardiles COM Phx Internal Medicine Pharmerit International 01/2021
SBIR OTA FA8649-20-9-9145 Raman COVID screener Contract $70,000.00 Research Kurt Denninghoff Dept of Emergency Medicine Botanisol Analytics, Inc. 09/2020
Stakeholder Alliance for Children with Robin Sequence (StARS): Building Capacity for PCOR Contract $249,054.00 Other Sponsored Activity Jonathan Skirko Otolaryngology Patient-Centered Outcomes Research Institute 02/2021
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First- Line Treatment of BRCA Non-Mutated Advanced... Contract $100,897.00 Clinical Trial Setsuko Chambers Cancer Center Division GOG Foundation, Inc. 08/2020
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants with Previously Treated Locally Advanced/Metastatic or Surgically Unresectable.. Contract $171,440.00 Clinical Trial Aaron Scott Cancer Center Division Incyte Corporation 05/2020
A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Hospitalized Patients with COVID-19 Contract $450,320.00 Clinical Trial Marilyn Glassberg Csete COM Phx Internal Medicine Regeneron Pharmaceuticals, Inc 12/2020
RELIEVE-HF: REducing Lung CongestIon Symptoms Using the V-WavE Shunt in adVancEd Heart Failure Contract $621,878.00 Clinical Trial Nancy Sweitzer Sarver Heart Center V-Wave Ltd. 11/2020
A Phase Two Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravenous USB002 to Treat Patients with Respiratory Distress due to COVID-19 Infection Contract $737,974.00 Research Sairam Parthasarathy Medicine United States Biotest Incorporated 05/2021
A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enzastaurin Plus R-CHOP Versus R-CHOP in Treatment-Naive Subjects with High-Risk Diffuse Large B-Cell Lymphoma Who Possess the Novel.. Contract $327,830.00 Clinical Trial Abhijeet Kumar Cancer Center Division Covance, Incorporated 01/2020
Ryan White HIV/AIDS Program AIDS Education and Training Centers Program COVID19 Response Contract $35,000.00 Other Sponsored Activity Stephen Klotz Medicine University of California, San Francisco 10/2020
ASHLine Expanded Services Contract $254,000.00 Other Sponsored Activity Mark Martz Health Promotion Sciences Arizona Department of Health Services 03/2021

Pages